Home - Clinical Trials Arena
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed success. MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.
Hepatitis B: Four trials to watch over the next 12 months
Jul 28, 2023 · Combination or monotherapy? ANRS Research Centre in France is running IP-CURE-B proof of concept (PoC) Phase II clinical trial (NCT05045261), which is due to end on 30 June 2024.
Obesity: Six trials to watch over the next 12 months
Jun 30, 2023 · According to a report by GlobalData, the market for obesity drugs is predicted to be worth $37.1bn in 2031.GlobalData is a parent company of the Clinical Trials Arena.. As more trials take place globally, not only will this help to provide a wider range of treatments for patients but will also assist the unmet need of lack of supply.Most of the …
Aruna to initiate clinical trial of AB126 for acute ischemic stroke
Jan 17, 2024 · Aruna Bio co-founder and chief scientific officer Steven Stice said: “We are thrilled with this validation from the FDA, which not only positions AB126 as the first exosome to enter human clinical trials for a neurological indication, but …
A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
Oct 1, 2024 · Cobenfy is also being developed as an adjunctive therapy in patients who have an inadequate response to atypical antipsychotic monotherapy. The ongoing Phase III ARISE trial is a six-week, randomised, double-blind, placebo-controlled, multicentre, outpatient study in patients with schizophrenia with an inadequate response to their current atypical antipsychotic treatment.
Lebrikizumab, Tralokinumab and Dupilumab compete in AD space
Oct 8, 2024 · Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space. The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience and cost-effectiveness.
XBiotech halts all rheumatology research after missing Phase II ...
Dec 24, 2024 · XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases while it “seeks to understand the outcome” from a Phase II study of its arthritis treatment Natrunix that failed to meet its primary endpoint.
GSK ceases HSV vaccine - a chance for Moderna and BioNTech
Sep 25, 2024 · GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary efficacy goals.. The vaccine aimed to reduce lesions in patients with recurrent genital herpes – a high unmet medical need. Although deemed safe, its lack of efficacy led to GSK’s decision not to ...
Most significant clinical trials of 2024
Dec 23, 2024 · Most significant clinical trials of 2024. From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.
IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections. As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden.